Table 3:

Relations between patients' characteristics and PRU^a

Clinical and Laboratory Variables	P	PRU
Sex (male)	<.001	244 ± 68 vs 291 ± 78
Age (younger than 65 years)	.028	268 ± 80 vs 295 ± 72
Body weight (≥60 Kg)	.031	267 ± 78 vs 292 ± 76
CPG medication (≥7 days)	.003	230 ± 96 vs 283 ± 74
Combination antiplatelet medication (yes)	.175	263 ± 83 vs 281 ± 76
Hypertension (no)	.745	275 ± 78 vs 278 ± 78
Diabetes mellitus (yes)	.184	251 ± 99 vs 279 ± 76
Statin use (no)	.198	274 ± 78 vs 293 ± 77
Smoking status (current or past smoker)	.071	256 ± 73 vs 282 ± 79
Alcohol intake (yes)	.157	260 ± 76 vs 280 ± 78
Hematocrit level (≥38%)	.008	263 ± 73 vs 293 ± 81
Platelet count (<227 × 103/μL)	.562	274 ± 80 vs 280 ± 76
Total cholesterol level (<200 mg/dL)	.232	273 ± 80 vs 288 ± 71
HDL cholesterol level (≥40 mg/dL)	.225	275 ± 79 vs 292 ± 69
LDL cholesterol level (≥130 mg/dL)	.608	273 ± 75 vs 280 ± 78
Triglyceride level (<200 mg/dL)	.091	274 ± 77 vs 299 ± 72
Procedure-related thromboembolism (no)	.061	274 ± 78 vs 318 ± 54

^aA group of patients denoted within the parentheses showed decreased residual platelet activity.